HomeHepatology
Hepatology
NASH has 50% higher death rate than NAFLD
A population-based cohort of almost a million people in the UK found that the chances of dying from non-alcoholic steatohepatitis (NASH), over a 14-year period, was approximately 50% higher than for those with non-alcoholic fatty liver disease (NAFLD).
In-patient cirrhosis deaths plummet
The largest US sampling to date found 'dramatic improvements' in the survival of patients with cirrhosis and liver failure.
NAFLD promotes coronary artery calcification
Non-alcoholic fatty liver disease (NAFLD) plays a role in the early stages of coronary atherosclerosis and in its more severe form it can also promote the development of coronary artery calcification (CAC).
HCV increases cancer risk 'significantly'
Cancer rates in patients with the hepatitis C virus (HCV) were significantly increased compared to the non-HCV cohort.
Study to look at new ARV tx for HCV
The US National Institutes of Health has launched a clinical trial to examine whether primary care physicians, nurse practitioners and physician assistants, can use a new antiviral therapy as effectively as specialist physicians to treat people with hepatitis C virus (HCV) infection alone, or co-infected with HIV.
Immunosuppressants may re-activate HBV
Individuals previously infected with the hepatitis B virus (HBV) who receive chemotherapy or immunosuppressive treatment may be at risk of reactivating the disease according to a Saint Louis University study.
Erectile dysfunction drugs to treat liver sepsis
Drugs to treat erectile dysfunction might be able to protect the liver from damage caused by sepsis, according to University of Pittsburgh researchers on mice.
Study reverses thought on cirrhotic patients with type 2 diabetes
Researchers at Mayo Clinic have released a new study reversing current thought on the treatment of cirrhotic patients with type 2 diabetes. News-Medical reports...